Acurx Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Net cash plus risk-adjusted pipeline option value: $10.66M cash and no debt divided by 5.27M shares equals $2.02 per share in net cash, plus an estimated $0.48 per share of risk-adjusted option value for ibezapolstat, a Phase 2/3 first-in-class antibiotic for C. difficile infection.

Reasoning: Acurx is a pre-revenue clinical-stage biotech, so a standard cash-flow DCF is not applicable; net cash provides a defensible valuation floor, and the company's shares currently trade below this cash value, implying the market assigns little to no value to the clinical pipeline.